Search

Author/Creator English, Brett A

1. P139 OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) – PRECLINICAL AND EARLY CLINICAL DEVELOPMENT. (7th February 2019)

Authors:
Lindstrom, Beatriz F; Ruckle, Jon L; Turner, Stewart A; Stauber, Kathe; Brierley, Stuart M; English, Brett A; Yacyshyn, Bruce
Journal:
Inflammatory bowel diseases
Issue:
Volume 25(2019)Supplement 1
Page Start:
S64
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease. Issue 1 (24th October 2020)

Authors:
Yacyshyn, Bruce R; Hanauer, Stephen; Klassen, Preston; English, Brett A; Stauber, Kathe; Barish, Charles F; Gilder, Kye; Turner, Stewart; Higgins, Peter D R
Journal:
Crohn's & colitis 360
Issue:
Volume 3:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗